Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Scorecard - MDSpire

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • By

  • Lee M. Kaplan

  • Elena Startseva

  • Carel W. le Roux

  • Sean Wharton

  • Biykem Bozkurt

  • Daniel F. Mazo

  • Jessica von Schlippenbach

  • Sandra González Maldonado

  • Samina Ajaz Hussain

  • Guy W. Neff

  • Yaneicy Gonzalez Rojas

  • Charles Smith

  • Ramy Younes

  • Arun J. Sanyal

  • June 7, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy of Survodutide in Adults with Obesity and Metabolic Dysfunction-Related Steatotic Liver Disease: Results from the SYNCHRONIZE-MASLD Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults with obesity and at-risk MASLD
Care Setting

Key Highlights

  • additional_context

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of MASLD requires hepatic steatosis and at least one cardiometabolic risk factor (e.g., hypertension, diabetes).
  • Formal diagnosis and staging of MASH requires liver biopsy.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • expanded_info

        Related Resources & Content

        Original Source(s)

        Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

        • by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal

        • June 7, 2026

        Related Content

        T cell dysfunction and metabolic disruption in chronic hepatitis C virus infection

        Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages

        Associations between prevalent unhealthy lifestyles and the gut microbiota: a comprehensive multi-database bibliometric analysis of pathogenic mechanisms and clinical trajectories